{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6JqZ8KDA","lastupdate":"2023-07-07T00:00:00.000Z","update_date":"2023-07-07T00:00:00.000Z","lastModified":"Sep 16, 2025","active":1,"confidence_score":91,"confidence_score_reason":"founding month, markets, not claimed","urlname":"shl-telemedicine","minimal_profile":null,"status":"Public","fullstatus":"Public on SIX on Apr, 2000<br>Public on NASDAQ on Mar, 2023<br>","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$S9E14tNcj9ZrdNPXmbrcSJ7sLTB21dcNeaeBRXxwGJJeDoXMxYYnAG","name":"SHL Telemedicine","oneliner":"Home-based Heart-monitoring Systems","registrar":"512527383","website":"https://www.shl-telemedicine.com","careerspage":"https://www.shl-telemedicine.com/jobs","founded_month":1,"founded_year":1987,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCL9MgtVZKmmqbdST-AARJag","facebook":"https://www.facebook.com/shahal.co.il","linkedin":"https://www.linkedin.com/company/351032","instagram":""},"social":["https://www.facebook.com/shahal.co.il","https://www.youtube.com/channel/UCL9MgtVZKmmqbdST-AARJag","https://www.linkedin.com/company/351032","https://apps.apple.com/il/developer/shl-telemedicine-ltd/id456576629","https://play.google.com/store/apps/developer?id=SHL+Telemedicine+Ltd."],"flattenedsociallinks":"https://www.facebook.com/shahal.co.il|https://www.youtube.com/channel/UCL9MgtVZKmmqbdST-AARJag|https://www.linkedin.com/company/351032|https://apps.apple.com/il/developer/shl-telemedicine-ltd/id456576629|https://play.google.com/store/apps/developer?id=SHL+Telemedicine+Ltd.","apps":{"appstore":"https://apps.apple.com/il/developer/shl-telemedicine-ltd/id456576629","googleplay":"https://play.google.com/store/apps/developer?id=SHL+Telemedicine+Ltd."},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":97,"patent":0,"raised":109000000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"SHL Telemedicine develops ECG and supporting devices, platforms, and software for home care. The company aims to increase users' chance of survival in the event of a heart attack and to generally improve quality of life after a medical emergency. SHL systems are intuitive, compact, and sophisticated; the company's ECG devices can record 12 hospital-grade ECGs within seconds.\r\n\r\nAt the heart of the company's service offering is its telemedicine center. The center is staffed around the clock by a skilled, professional, and specially trained medical team to ensure appropriate evaluation and care in line with common medical procedures.\r\n\r\nEach SHL user receives a complete and secure personal health record that includes all relevant information, including demographic data, medical history, and medical baseline data provided to SHL by its users. This information can also include the results of previous ECGs as well as blood pressure and weight readings.\r\n\r\nSHL also develops full hospital-grade ECG devices. Such devices allow users to send ECGs remotely to their physician, cardiologist, or telemedicine center for evaluation.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97235612212","country":null,"address":{"israeli":[{"id":"efb095bf-95be-4abf-a385-99e173d3b0e6","city":"Tel Aviv-Yafo","type":null,"address":"Yigal Alon 90, Tel Aviv, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"c19b22c3-1fad-4c3e-ae1e-8bf52453b382","city":"Hauppauge","address":"350 Motor Pkwy, Hauppauge, NY 11788, USA","country":"United States","placeid":null},{"id":"d91838be-17ab-42b0-b5ce-1bb6cf844dc9","city":"Mnchen","address":"Balanstrae 69, Munich, Bayern, Germany","country":"Germany","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"Hrz3eeAXngf5hpQo2E2m1dbIH7NYBtKYWmr0MsxKTRYt3yuGZozmhr","date":"Sep 16, 2025","link":"https://finance.yahoo.com/news/shl-telemedicine-first-half-2025-041615543.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","round":null,"company":"SHL Telemedicine","layoffs":null,"summary":"SHL Telemedicine reported a flat revenue of US$27.9 million for the first half of 2025, with a net loss widening by 8.7% to US$4.35 million. The loss per share increased to US$0.27 from US$0.24 in the first half of 2024. Despite these financial challenges, the companys shares have risen by 9.4% over the past week. The article highlights that SHL Telemedicine is showing three warning signs in investment analysis, with two being particularly concerning. Simply Wall St provides a general analysis based on historical data and forecasts, emphasizing that it is not financial advice.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["revenue","net loss","share price","dividend","investment"],"date_of_event":"September 16th 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"T8nW8oKBXeyFtBjqeWjKrqCoSvLgfjNVXsKlaF1oGhFFcvIo7KimAh","news_summary":"SHL Telemedicine First Half 2025 Earnings: US$0.27 loss per share (vs US$0.24 loss in 1H 2024)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NgsKG485TRoseQcvIJ9rMBiWcyiFE1wOJujfD04ZFg0TjNiVBfDD84","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/thales-hii-partners-develop-advanced-070000956.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"HII","layoffs":null,"summary":"HII and Thales have successfully integrated the Thales SAMDIS1 600 sonar with HIIs REMUS 620 unmanned underwater vehicle (UUV). This integration enhances autonomous mine detection and undersea security capabilities, marking a significant milestone in undersea mine countermeasure technology. The exercise, completed in August at HIIs Pocasset facility, highlights the strength of industry partnerships in delivering advanced solutions. HII and Thales collaboration leverages their leadership in unmanned and underwater systems, offering enhanced capabilities for naval forces and partners worldwide.","partners":["Thales"],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["integration","sonar","UUV","autonomous","security"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"using","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"l2gsueMYbVblMxUBU2doEO1Zqs8b7DbBcJDhOf0wZWdLCptK1IEMYa","news_summary":"Thales and HII partners to develop advanced autonomous undersea mine countermeasure capabilities","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TQCcp2mtAv7XxMRA8rkbz5C4EyjMShMxEqt3Bw66Aoi58HPetSx1Kl","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/interparfums-enxtpa-itp-closer-look-123118633.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, market sentiment","round":null,"company":"Interparfums","layoffs":null,"summary":"Interparfums has been experiencing a downward trend in its stock price, losing about 21% of its value over the past year despite showing solid single-digit annual growth in revenue and net income. The companys shares are trading at a price-to-earnings (P/E) ratio of 19.4x, which is lower than the industry averages, suggesting that the market is cautious about its future growth prospects. While the stock might be undervalued based on its earnings power, a decline in consumer demand or margin pressures could further impact its valuation. The SWS DCF model suggests the stock might be overvalued, indicating differing risk assessments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["valuation","P/E ratio","market sentiment","stock performance","consumer demand"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"QxPmdZGAZDTNdh1hX8Pa2209uE8EJ2kv8EXAkgG1w7fMGDx0eM8Q4e","news_summary":"Interparfums (ENXTPA:ITP): A Closer Look at Valuation as Market Sentiment Shifts","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Lsm91NVZRRa5lhfpCVhC09tNtXwEFmQSbXsYtjWmENAsb8RhefQYlP","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/lenzing-wbag-lnz-valuation-discount-124617151.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Lenzing","layoffs":null,"summary":"Lenzing, a company listed on the Vienna Stock Exchange (WBAG:LNZ), has experienced a volatile stock performance, with a 12% drop over the past year. Despite some revenue growth, the company has faced widening net losses, leading to a lack of sustained investor confidence. Lenzings price-to-sales ratio is significantly lower than the industry average, suggesting it may be undervalued. However, persistent net losses and market volatility pose risks to its valuation. The companys shares are considered undervalued based on a discounted cash flow model, but future market sentiment will depend on whether profitability forecasts materialize.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","market sentiment","revenue growth","net losses"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€88.89","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"l06V6JWWPKqOcVwodv15SiJ5bSfRdsrvHop64sWyajznKKs9NIEBX0","news_summary":"Lenzing (WBAG:LNZ) Valuation: Is the Discount Reflecting Opportunity or Ongoing Concerns?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"QJXcaqpPTZaHDNS66X1O1Wv4xoSVQ19LyPzT0Q0RQt3J86j029AdrM","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/vivendi-q1-earnings-miss-impact-130154741.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Vivendi","layoffs":null,"summary":"Vivendis stock has experienced significant volatility, with a 222.4% surge over five years and a 41.7% return in the last year, but a recent 5.4% decline in the past month. Despite optimism about growth prospects, the companys valuation is concerning, scoring 0 out of 6 on a valuation assessment. The Dividend Discount Model (DDM) reveals negative return on equity and payout ratio, indicating unsustainable profits and dividends. The implied dividend growth rate is negative, suggesting future dividends may decrease. Investors are advised to consider these factors before making investment decisions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","dividends","market sentiment","financial metrics"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"sSYIQ5Jakwn7wZLXL6h7kHKEbC7qfxsyVkxP8NocuNrEoLyaOf24Qk","news_summary":"How Will Vivendi’s Q1 Earnings Miss Impact Its 2025 Market Valuation?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mOIzOpDkrcQNRvyzqBQFKz7gRCiSVc3V54PvsXzlRBG7121NO0WDvH","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/assessing-veolia-environnement-enxtpa-vie-130412961.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Veolia Environnement","layoffs":null,"summary":"Veolia Environnement has been attracting investor attention due to subtle shifts in its share price, despite no major news events. Over the past year, its share price has been relatively flat, with a small gain of under 1%. However, the company has seen significant long-term growth, with returns of 40% and 87% over the past three and five years, respectively. Analysts consider Veolias shares undervalued, trading at a discount to estimated fair value. The companys growth is driven by the expanding need for climate adaptation infrastructure and high renewal rates of long-term agreements. Despite the optimistic outlook, potential integration challenges from recent acquisitions or market weaknesses could pose risks.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["share price","undervaluation","growth assumptions","recurring revenue","climate adaptation"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€35.07","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FHw9nXZ3vXqrrSqoV6YMG8S7IcDjA7cG5dszXNAADH1m3miTfq8Qqb","news_summary":"Assessing Veolia Environnement (ENXTPA:VIE) Valuation as Investors Eye Subtle Shifts in Utility Stocks","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"WQsMlR8qqPGTf65SXz1mkNlmNxtG2hNIEGfavBRHriYn4w3TKWVqs2","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/telenor-ob-tel-market-underestimating-130228250.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, market-position","round":null,"company":"Telenor","layoffs":null,"summary":"The article discusses the current market position and valuation of Telenor, highlighting its recent performance and investor interest. Telenor has shown a 33% return over the past year, with a 29% gain year-to-date, indicating growing interest despite a lack of headline events. The companys focus on core markets has resulted in steady revenue growth and increased net income. Telenor is trading at a higher P/E ratio compared to the broader European telecom industry, suggesting optimism about its future profitability. However, concerns about a slight premium to analyst price targets and modest revenue growth could challenge further upside potential.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["valuation","P/E ratio","revenue growth","market position","investor interest"],"date_of_event":"Sep 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$397.82","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"olWccHT1yvuUz99KtwmOullNSwbKHnM9lvQr5acGeMQBScBEXA8jDg","news_summary":"Telenor (OB:TEL): Is the Market Underestimating Its True Value?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"w7eEkmMnhTGvN2bq3VxSotrm8oTG8lIRcmu83CEvN5SDCIsiJg2Yhy","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/kingspan-group-shares-jump-7-123559158.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, sustainability","round":null,"company":"Kingspan Group","layoffs":null,"summary":"Kingspan Groups stock has been gaining attention from investors due to its potential for value and growth, despite a modest year-to-date return of 1.6% and a five-year gain of just over 5%. Recently, the share price increased by 7.5%, reflecting a shift in investor sentiment. The companys focus on sustainability and innovative insulation solutions is expected to broaden growth prospects. A Discounted Cash Flow (DCF) model suggests that Kingspan is undervalued, with its intrinsic value per share estimated at €95.56, indicating a 25.5% discount compared to the current share price. This presents a compelling opportunity for long-term investors.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["valuation","sustainability","insulation","growth","investment"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"N/A","AI technology developing/using":"N/A","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"slOWGutp57vsvXCnXOmUjegFFFXy4npYcLLUap78BxrZwlsrHhvVZz","news_summary":"Kingspan Group Shares Jump 7.5% Amid Sustainability Push: What Does This Mean for Valuation in 2025?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"aOWzflASMH1gUt3wq34SHX0gHZfqbQDAWR85t7P6kVcBGX6pXmvp1e","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/seb-shares-slide-31-2024-120612182.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"SEB","layoffs":null,"summary":"SEB has experienced a significant decline in its stock value, dropping 31.2% over the past year and 45.6% over the past five years. Despite these losses, the company is considered undervalued based on valuation scores, with a Discounted Cash Flow (DCF) model suggesting a 62.8% discount to its fair value. SEBs Free Cash Flow is projected to rise significantly over the next decade, potentially reaching close to €1 billion by 2035. This presents a potential opportunity for value-focused investors looking for a turnaround. The article discusses the importance of valuation metrics and the potential for SEB to recover based on its intrinsic value.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock decline","valuation","cash flow","undervaluation","investment opportunity"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"p1UGeKp1NtUMXNCkHr7WvmNNj5eJ0w3CWYsmlxGiW1zlMeNSs5Heoj","news_summary":"SEB Shares Slide 31% in 2024 Is the Current Price Attractive?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"erSCBeKJkxgDVhEpelhyxaFf9Ujz5eCadPA6raee4ymlEM3n5Nkyxz","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/taking-stock-schneider-electric-enxtpa-124857290.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Schneider Electric","layoffs":null,"summary":"Schneider Electric has been attracting attention from investors due to fluctuations in its stock price. Despite recent cooling in momentum, the companys stock has shown a steady 5% increase this year and an impressive 84% total return over the past three years. The market is currently reassessing Schneider Electrics future value, with many viewing it as undervalued by 10.6%. The company is poised to benefit from the global shift towards electrification and renewable energy, which supports long-term revenue growth. However, potential risks include margin pressure and slower recovery in key segments. Schneider Electrics share price is considered more expensive compared to other European electrical companies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock","valuation","growth","energy","market"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XAox0REtWl0Zk6UTBpgxsAVS5JCBMAvrVavwJIFFFiysRKsrDmMXtd","news_summary":"Taking Stock of Schneider Electric (ENXTPA:SU): Is the Current Valuation Justified?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ZEJnB0j2pDuRMPLnUP1HSBYmBcKBZZAwZZgbp0akJkwJU850YNMYz5","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/capgemini-enxtpa-cap-analyzing-valuation-124454055.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["valuation","digital transformation"],"round":null,"company":"Capgemini","layoffs":null,"summary":"Capgeminis stock has been experiencing subtle price movements, raising questions about its valuation. Despite a 28% dip in the past year, the company has seen a 17% gain over five years. Analysts believe Capgemini is trading at a discount to its fair value, driven by its leadership in cloud, data, and AI, which positions it for future growth. The company is expected to benefit from increased demand for digital transformation, leading to higher-value contracts and potential revenue expansion. However, weak demand in key regions and pricing competition could pose risks to this optimistic outlook.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["stock","valuation","AI","cloud","digital"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€175.93","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"N/A","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aVyBA9JcnKgskIBhXf78ThkBhXTEdFpQa2wZPFx3ygmF7GvyLKzWjc","news_summary":"Capgemini (ENXTPA:CAP): Analyzing Valuation Signals Behind Recent Quiet Share Price Moves","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"WOuMUj50dJ6z0hvDHj8Vtiwzb9jM3t1lJTxpO7fJgL96OwyWTVYj6h","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/lvmh-share-transactions-disclosure-154700501.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"share transactions","round":null,"company":"LVMH","layoffs":null,"summary":"LVMH, a leading luxury goods company, disclosed its share transactions carried out from September 1st to September 5th, 2025. This disclosure was sent to the AMF on September 9th, 2025, and is publicly available on the companys website under the regulated information section. LVMH is represented in various sectors, including Wines and Spirits, Fashion and Leather Goods, Perfumes and Cosmetics, Watches and Jewelry, and Selective Retailing. The press release provides contact information for analysts, investors, and media across different regions, including France, Italy, the UK, the US, and China. The article does not indicate any significant impact on the companys growth or mention any specific financial transactions beyond the disclosure of share transactions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["share transactions","brands","divisions","contacts","disclosure"],"date_of_event":"September 9th, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-neutral","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"none;"},"sentiment":"growth-neutral","analysisId":"D5cFBF4PDgqEScwvISJTwVuXdgdIdoY7ZX1jmzF5sdwwd4ObNed0Xm","news_summary":"LVMH: Share transactions disclosure","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5nAJ90tcrjOzUWOHxIblFYXd803ggIK4g4twSkCJLNsLGX2ZGEbTUd","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/edp-enxtls-edp-closer-look-123528415.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"EDP","layoffs":null,"summary":"EDP (ENXTLS:EDP) has experienced a modest increase in share price, despite the absence of major announcements, suggesting a potential market reassessment of the companys value. The company is perceived as undervalued by approximately 12% based on forward-looking earnings and growth prospects. EDP is focusing on significant investment growth in electricity networks, driven by electrification, infrastructure modernization, digitalization, and renewable integration. These initiatives are expected to enhance revenue through expanded regulated asset bases and improved demand. However, regulatory uncertainty in Iberia and currency fluctuations in Brazil pose potential risks. The markets perception of EDPs valuation varies, with some viewing it as undervalued and others considering it expensive compared to industry standards.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["valuation","investment","electricity","regulation","currency"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€4.27","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dCoaFAWn78ntNhNCKuKfJj3QnOhvRGUOrmALtBtdp8ktf4yuBRAW3K","news_summary":"EDP (ENXTLS:EDP): A Closer Look at Valuation as Market Reassesses Prospects Without Major News","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"M2cvIwSMWz9LgTZy8jy5vvVDVqm742ifi7MeWVU3aeWmCkqHUvcC5P","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/soci-t-fonci-lyonnaise-enxtpa-131549128.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, profitability","round":null,"company":"Société Foncière Lyonnaise","layoffs":null,"summary":"Société Foncière Lyonnaise has experienced a nearly 13% increase in its share price over the past year, despite quieter trading days and no major headlines. This growth contrasts with more muted movements over the past month and three years, suggesting a longer-term positive trend. The company’s annual revenue has slightly declined, but net income growth remains strong, shifting market focus towards profitability. Trading at a P/E ratio of 13.6x, below the French market average and its global office REITs peers, the stock appears undervalued. This suggests potential underpricing of forecasted profit growth or unrecognized profitability improvements, offering a potential bargain for investors.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["share price","valuation","profitability","P/E ratio","market sentiment"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Rpvf9B2PIujXlpBp43KKy15NUNtNQItNY5BPLpdm8MFH955zKzLhWz","news_summary":"Société Foncière Lyonnaise (ENXTPA:FLY): Assessing Valuation After a Year of Solid Share Price Gains","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5kPin4I8eMjEVZsaacG4W3RVUFlxc7dYetXtEuprKuOYviMr1AZnH9","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/assessing-mediobanca-bit-mb-valuation-125655725.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Mediobanca Banca di Credito Finanziario","layoffs":null,"summary":"Mediobanca Banca di Credito Finanziario has shown significant stock performance, with a 37% increase year-to-date and 196% over three years. The banks growth is driven by its Wealth Management and Private Banking expansion, supported by strong net new money inflows and increased hiring in sales/advisory roles. Analysts consider Mediobanca fairly valued, with its share price closely aligned with calculated fair value. However, increased competition in wealth management or a cooling Italian economy could challenge this outlook. Despite being more expensive than many European peers, Mediobancas strategic repositioning and steady growth could reshape margin expectations.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock movement","valuation","wealth management","revenue growth","competition"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€20.06","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1knHzvW22TPtjMaDp8E1kwimVh78AyrCIbe93lfMf7h95JsOnHMU8k","news_summary":"Assessing Mediobanca (BIT:MB) Valuation After Notable Multi-Year Gains Without Major Headlines","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ZNfD4yD2e5BWY1kMEJwKByhSp0gXqLiBTCPLNvP8yShQWDGE50SMtQ","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/outokumpu-signs-mou-boston-metal-060700547.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"sustainability","round":null,"company":"Outokumpu","layoffs":null,"summary":"Finnish steelmaker Outokumpu has signed a memorandum of understanding with U.S.-based Boston Metal to enhance the production of carbon-free metals. This partnership aims to develop a joint project utilizing Outokumpus chromium material from its Kemi mine in Boston Metals molten oxide electrolysis technology. The collaboration is part of Outokumpus EVOLVE strategy for 2026–2030, focusing on reducing greenhouse gas emissions in steel production. This initiative aligns with the clean energy transition and environmental sustainability goals.","partners":["Boston Metal"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["carbon-free","sustainability","partnership","technology","steel"],"date_of_event":null,"product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YQC2deSQ16xH3NBVcNWBGUZEKo4GTq83jWXpHWQwSNGvzsj7iH37cJ","news_summary":"Outokumpu signs MoU with Boston Metal to enhance production of carbon-free metals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KZw5gxRbIJ48UXK7VlsD8u89tFMOdPvzJX7BocDJW4JBWmBhLzuyo2","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/assessing-k-benhavns-lufthavne-cpse-124631112.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Københavns Lufthavne","layoffs":null,"summary":"Københavns Lufthavne (CPSE:KBHL) has experienced a notable increase in its stock performance, with a 9% rise since the start of the year and a 67% return over the past year. This growth has prompted investors to reassess the companys valuation and growth prospects. The companys current price-to-earnings (P/E) ratio is significantly higher than the industry average, suggesting that the market expects above-average growth or profitability. However, the elevated valuation raises concerns about whether the market has already priced in future growth potential. Despite the positive sentiment, slower revenue growth or changes in passenger trends could impact the companys valuation.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","growth prospects","P/E ratio","market optimism"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"r7dfsBByURQPWzqzgaRhowRw3Ex7U1GCwWCyygdAjQBM2rI5a82Ril","news_summary":"Assessing Københavns Lufthavne (CPSE:KBHL) Valuation Following Sustained Stock Momentum","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mVIK27Tj97XuEMljyjazc6rcj1ybGFAghIraAHbEVNRzralU143iFs","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/kesko-hlse-keskob-fresh-look-124908438.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Kesko Oyj","layoffs":null,"summary":"The article discusses the recent performance and valuation of Kesko Oyjs stock. Despite a 9% total return over the past year and a 4% gain year-to-date, the stock has seen negative performance in the past three months, raising questions about its future trajectory. The companys P/E ratio of 20.1 is higher than the industry average, indicating that investors may be expecting better future performance. However, with earnings growth forecasts trailing the industry, the stock might be overvalued. A DCF model suggests the stock is undervalued, contrasting with market ratios that indicate overvaluation.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock","valuation","P/E ratio","growth","investors"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"YYbqAOejVWjrPm90BwKYMnGbtWGDBLMNZKy4rTyYTo0HBLRLfoNZM7","news_summary":"Kesko (HLSE:KESKOB): A Fresh Look at Valuation Following Recent Share Price Shifts","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Ls2jkd5EGL8nFZEpZh23LhJZV5Kcf6sRAq7pTB8Xa4HtFYGeVJQ8Q2","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/transactions-connection-share-buyback-programme-064200658.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"share buyback","round":null,"company":"Pandora A/S","layoffs":null,"summary":"Pandora A/S announced a new share buyback programme on 5 February 2025, aiming to reduce its share capital and fulfill obligations from company incentive programmes. The programme, compliant with EU market abuse regulations, will repurchase shares up to DKK 4.0 billion from 6 February 2025 to 30 January 2026. The first tranche of DKK 1.3 billion ran from 6 February to 6 June 2025, and the second tranche of DKK 1.35 billion from 10 June to 22 August 2025. Danske Bank is managing the third tranche of DKK 1.35 billion, running from 25 August 2025 to 30 January 2026. As of 5 September 2025, Pandora owns 2,922,553 treasury shares, 3.7% of its share capital.","partners":["Danske Bank"],"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["share buyback","capital reduction","incentive programmes","market regulation","financial transactions"],"date_of_event":"5 February 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kz8b2ff59mPRUdqztTO3KHLo5pzoRZLTzFeAhN1ZaYv8EB3s3kIjGs","news_summary":"Transactions in connection with share buyback programme","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5tj3Rd2G0nigbG73Ew15srBEOjv3JAAkIK5waisRarLCxSKd1gNlNY","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/does-steep-20-drop-mean-132624523.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, stock decline","round":null,"company":"Rémy Cointreau","layoffs":null,"summary":"Rémy Cointreau has experienced a significant decline in its stock price, dropping 20.5% over the last year and 69.8% over the past three years. The recent slide is attributed to changes in global luxury demand and shifting consumer preferences. Despite the downturn, the companys future cash flows are projected to rise significantly, suggesting that the stock might be undervalued. Analysts estimate that Free Cash Flow will grow from €50.66 million in 2026 to €229.64 million by 2035. The Discounted Cash Flow model indicates an intrinsic value of €81.56 per share, implying a 37.1% discount from the current trading price.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["valuation","stock decline","cash flow","luxury demand","consumer preferences"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Tg14vUNvFFEYC7XSUsQkk3Qhk8WnY7sJ3zDfXeKfv9qs1TS2ZEL7DO","news_summary":"What Does the Steep 20% Drop Mean for Rémy Cointreau’s 2025 Outlook?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Cw4sbrmKnLQbrCRBkJ8y1HjoaXzUfJ2ygxkrQcNjdkRw5cqx8dylct","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/fresh-look-lotus-bakeries-enxtbr-123348869.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["expansion","partnership"],"round":null,"company":"Lotus Bakeries","layoffs":null,"summary":"Lotus Bakeries has caught the attention of investors due to its perceived undervaluation and strategic initiatives. Despite a challenging year with a 28% drop in stock value, the company is seen as having growth potential. A strategic partnership with Mondelez aims to expand the Biscoff brand in India and develop new chocolate products in Europe. Additionally, a new production facility in Thailand is expected to support growth in the Asia Pacific region by mid-2026. These initiatives are expected to drive revenue growth and improve margins. However, risks such as delayed facility completion and raw material cost volatility could impact future valuations.","partners":["Mondelez"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["undervalued","partnership","expansion","valuation","risks"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€9,635.71","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8QtCvkjvIubt14SgPzax6Cy1PcOQ5GA1gF5bopaggyOPnPuTpaOMgF","news_summary":"A Fresh Look at Lotus Bakeries (ENXTBR:LOTB) Valuation as Investor Interest Quietly Grows","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YqiRkjIxjuXYe60PdtGo1J0UAa3X5S8HyUkc45dHv5KfacSTXZibCR","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/lagardere-set-growth-recent-resilience-123042309.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Lagardere","layoffs":null,"summary":"The article discusses the current state of Lagarderes stock performance and valuation. Despite a 4.9% decline over the past year, the stock has shown signs of recovery with a 0.2% increase in the past week and a 1.2% gain over the last month. Long-term performance is strong, with a 48.8% increase over three years and 31.8% over five years, indicating durable growth potential. The company is considered undervalued based on six key valuation metrics, with a Discounted Cash Flow (DCF) model suggesting the stock is trading at an 81.3% discount to its intrinsic value. Lagarderes robust cash generation capacity is highlighted, with projected Free Cash Flow growth over the next decade.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","cash flow","growth potential","media sector"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Jbi3hgulSu2rF460erYTQYF7Qd5DV2Rd0SL09QIxrsZwHw5xJCKpgl","news_summary":"Is Lagardere Set for Growth After Recent Resilience in the Media Sector?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bcMqe75hhpoxa605wHqW4kYdH88WeIjEyfVgOuHODvVcmim8lt2KJj","date":"Sep 9, 2025","link":"https://finance.yahoo.com/m/bc3253e4-4802-38cf-b9a2-eac28250ace8/french-industrial-output.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"economic decline","round":null,"company":"French Industrial Sector","layoffs":null,"summary":"The article reports a decline in French industrial output for July, with a 1.1% decrease compared to the previous month. The downturn is attributed to reduced production in key sectors such as transport manufacturing, electrical equipment, and pharmaceuticals. This decline signals a negative economic trend for the French industrial sector, impacting its growth prospects. The article does not mention any specific companies, partnerships, or investments related to this decline. The focus remains on the overall performance of the industrial sector and its implications for the broader economy.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["industrial output","transport manufacturing","electrical equipment","pharmaceuticals","economic performance"],"date_of_event":"September 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"M4TQiRcpqFVOrdGqMlS45GS31qbqHYHI3cnH0oEJqyhY0PBns5O4IO","news_summary":"French Industrial Output Retreated in July","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"PdGsu0hvpmw2XIZdV4Tqg2UtLSsPP3gNykq8eI88KJH3nP4KIeWkWS","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/huhtam-ki-oyj-managers-transactions-065500808.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"Huhtamäki Oyj","layoffs":null,"summary":"Huhtamäki Oyj, a leading global provider of sustainable packaging solutions, announced a managers transaction involving the acquisition of shares by its CEO, Ralf K. Wunderlich. The transaction took place on September 8, 2025, at NASDAQ Helsinki. Huhtamäki, with over 100 years of history and a strong Nordic heritage, operates in 36 countries and 101 locations worldwide. The company emphasizes sustainability in its innovative packaging products, which protect food, beverages, and personal care items. In 2024, Huhtamäki reported net sales of EUR 4.1 billion. The acquisition of shares by the CEO is seen as a positive indicator of confidence in the companys growth and future prospects.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["sustainable packaging","global provider","food safety","Nordic heritage","net sales"],"date_of_event":"2025-09-08","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"adYBQwcmyhSRtvmnCZfV1uEBAEyLpR7ezEqUcG7nMYXjzTbpUgIla8","news_summary":"Huhtamäki Oyj - Managers' Transactions (Wunderlich)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zTOvMyfSpnC4G2bMu6ce6dH1tImlnblBlkp3DQU9F5wqJtNBtqm9nG","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/minor-hotels-europe-americas-bme-130822121.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation, expectations","round":null,"company":"Minor Hotels Europe & Americas","layoffs":null,"summary":"Minor Hotels Europe & Americas has been maintaining a steady share price, which has caught the attention of investors. Despite a recent dip in revenue and net income, the company has shown strong long-term performance, delivering a 59% return over the past year. The stock appears undervalued with a P/E ratio of 11.2x, lower than the industry average, suggesting that the market might be underestimating its profit potential. However, the recent financial softening could limit future growth, raising questions about whether the current stock price reflects all future potential.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["valuation","P/E ratio","earnings","revenue","investment"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"OwO3gJWiEljw7UC3Jttx83rFHcmn37lnc9UHVVmf35SDfIu8OzTAFg","news_summary":"Minor Hotels Europe & Americas (BME:NHH): Exploring Valuation After Steady Share Performance","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"xCyZa27FTQIufXWdNQxF3sZJVF8mLtHvynVGVIiBtuJ0PZV1Fp8q4W","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/recent-earnings-mean-forvia-2025-130604365.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Forvia","layoffs":null,"summary":"Forvias stock has experienced significant fluctuations, with a recent 5.5% drop over the last week but a 24.5% rise year-to-date. Despite long-term declines, the company has shown a 22.9% increase over the past year. Analysts project an increase in Free Cash Flow from €657.4 million to €1.27 billion by 2035, suggesting potential undervaluation. The Discounted Cash Flow model estimates an intrinsic value of €49.51 per share, indicating a 77.8% discount compared to the current market price. This suggests that Forvia may be undervalued, presenting a growth-positive outlook.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","DCF model","cash flow","market sentiment"],"date_of_event":"2024","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lYKXxut4EnreL4pt2m0BILIn5G0miEWVSJHCWOB6W16WFJUjQvhSYo","news_summary":"What Recent Earnings Mean for Forvia’s 2025 Value Prospects","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ew3ZMYwHddtdzxwNvhWKvlf72xiD0PNLmyPl8isL13DXHcmxWwmb7M","date":"Sep 9, 2025","link":"https://www.motorfinanceonline.com/news/gateway2lease-sees-ev-enquiry-surge-after-government-grant-launch/","source":"www.motorfinanceonline.com","visible":1,"analysis":{"tags":"EV demand","round":null,"company":"Gateway2Lease","layoffs":null,"summary":"Gateway2Lease, a Midlands-based leasing broker, reported an 18% increase in electric vehicle (EV) enquiries in August, attributed to the UK Governments Electric Car Grant scheme. The scheme has boosted interest in models like the Cupra Born, Renault 5, and Renault Scenic. However, Gateway2Lease warned that fluctuating lease prices and changing eligibility criteria could affect customer confidence. The government recently adjusted the grant rules, introducing a new £42,000 price cap. Despite these challenges, Gateway2Lease remains optimistic about the schemes potential to increase EV accessibility. Both business and personal customers are increasingly willing to switch to EVs, reflecting a broader market trend.","partners":null,"customers":["business","personal"],"eventType":null,"investors":null,"confidence":9,"key_topics":["EV enquiries","Government grant","Lease pricing","Customer confidence","Market trend"],"date_of_event":"August 2023","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"obfhMiZDNLT8O5SglJ9gSIjXTAt8jYEw238DjTgdMswMuWm0e0iXBz","news_summary":"Gateway2Lease sees EV enquiry surge after government grant launch","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"auTNLyx18rD3pfSrNHnxhd4egfi28cUO9H6KU4KaPN9yK3bdyDBrc1","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/now-time-reassess-solvay-recent-120726540.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Solvay","layoffs":null,"summary":"Solvays stock has experienced short-term declines, with a 1.0% drop in the past week and a 2.7% decrease over the last month. However, over the longer term, the stock has shown significant growth, with an 86.0% increase over three years and a 112.0% rise over five years. This suggests potential for growth despite recent volatility. The companys valuation is currently considered to be around 18.1% undervalued based on a Discounted Cash Flow model, which estimates Solvays intrinsic value at €33.81 per share. Analysts project a turnaround in Free Cash Flow, with positive figures expected by 2026. The stocks movements are influenced by broader market trends in the European chemicals sector.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock performance","valuation","cash flow","market trends","growth potential"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qB3kqVPLiWLHQRcot9KZzuuiGQ4qZPraF0Rlz1EYeTqLbhpGoOJ2BG","news_summary":"Is Now the Right Time to Reassess Solvay After Recent Sector Volatility?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"nAcXLoYRaaNwZoG9nesoSGMR9Gx0TyiU0Eg80GysaBMVsbCSdwBisa","date":"Dec 19, 2024","link":"https://finance.yahoo.com/news/docgo-shl-telemedicine-partner-put-124511186.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"partnership expansion","company":"DocGo","layoffs":null,"summary":"DocGo has announced an expanded partnership with SHL Telemedicine to integrate the SmartHeart portable 12-lead ECG device into its mobile healthcare units. This collaboration aims to improve access to cardiovascular diagnostics, particularly in underserved areas across the United States. The initial phase will focus on California, targeting rural communities and healthcare deserts. This partnership addresses the lack of cardiologists in many U.S. counties and aims to enhance patient outcomes by providing advanced diagnostics directly to patients homes. The expansion is part of DocGos broader strategy to improve healthcare accessibility and outcomes through innovative technology.","partners":["SHL Telemedicine"],"customers":null,"investors":null,"confidence":10,"key_topics":["partnership","healthcare","technology","cardiovascular","expansion"],"date_of_event":"11/8/2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BHARmHfH7Yob6DzzendeKcWB8BQC1dPRGbrVx041jbPcDMWVTr10IY","news_summary":"DocGo and SHL Telemedicine partner to put 12-lead devices in health care units","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"I47sOX57dyM0Agd0Pv4X5BZ5zMTej2WrOwSSasp8MfEwnyIZhjEjKg","date":"Dec 18, 2024","link":"https://finance.yahoo.com/news/docgo-shl-telemedicine-partner-revolutionize-123500544.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"partnership expansion","company":"DocGo Inc.","layoffs":null,"summary":"DocGo Inc., a leading provider of mobile health services, has announced an expanded partnership with SHL Telemedicine to integrate the SmartHeart® portable 12-lead ECG device into DocGos mobile health care units. This collaboration aims to enhance cardiovascular diagnostics accessibility, especially in underserved areas across the U.S. The partnership will initially focus on California, addressing healthcare access challenges in rural communities. By equipping mobile health vehicles with advanced ECG technology, DocGo aims to improve patient outcomes and reduce healthcare costs by facilitating early intervention and preventing emergency room visits. This expansion underscores DocGos commitment to delivering scalable, patient-centric healthcare solutions and transforming traditional healthcare delivery models.","partners":["SHL Telemedicine"],"customers":null,"investors":null,"confidence":10,"key_topics":["partnership","healthcare","technology","cardiovascular","accessibility"],"date_of_event":"December 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QNkCHMBZQNxt4wIXgmbS4dSQAhIvjlY8Kuzf4471GPBBp6mQ3rD6dD","news_summary":"DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lzAuvxVe64mQIeux9TJvrH6qYPnYsXO7Q7XGttHid8LNPr8vMYrIWo","date":"Jul 29, 2024","link":"https://www.businesswire.com/news/home/20240728163877/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"stE9bASpQgexbUQb4kshvnljvjaCtD7GJU1YjnIUadHWLW7KSNtzNt","news_summary":"SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"2BVITiKVEG7qHiXckyKm8X00q1kiWFO4iQIIj5GA94SH4Bis98vjs0","date":"Jun 20, 2024","link":"https://www.businesswire.com/news/home/20240620051822/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"yH867Tc8zPakoHOToEanDGngfyise9cOJqlwovJHZY1KgYvjJk98aD","news_summary":"SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"XL2jxVUmVJ7fm5wRQA952sxgJw1Sam83IbVMQ5a4PbJO21x0HVDFIV","date":"May 21, 2024","link":"https://www.businesswire.com/news/home/20240520051489/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"mM4hK87m4a27E0RHAX0uK2alLFTYfZn5BM3x0kOPQRJkSV7jWBl8Sw","news_summary":"SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ixcLRFftPP2UfItbpH1wh0AgNRPfwtpYB1b3KmfiwfgdVdNT4fJi9y","date":"May 16, 2024","link":"https://www.businesswire.com/news/home/20240515833949/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"lXGD1FcfaQIVJ9zLb5rM2mw4J7FkajYbXHV7sN5ybqySOk1H2xHPVV","news_summary":"SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ccDp8e3q5kehis73hZXUr6VGmsHNBVPcf1rcedSGaPlEkM7TuMtgPE","date":"Apr 17, 2024","link":"https://www.businesswire.com/news/home/20240416477137/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"bu2JfJk4uDeka1VuObIutuWirZmEZaw4AX56s2hJjQFeUCOikhsF5F","news_summary":"SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"Nb4DrxEEbxEp4mpgUl8RolJc47GTtyWKCBM2VRfSFwP2BCnT3Eota0","date":"Apr 11, 2024","link":"https://www.businesswire.com/news/home/20240410735175/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"FQYBJVQRtmhuyw5gfmKXUv33mHj7SUhqvmX2LTta8pmMwhRlqjMNHN","news_summary":"Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"XVKhX0wd5tRFfxAU3BCpMhZcpc9aAhB3X4PYvRfbhsccsqe9YGUw25","date":"Apr 8, 2024","link":"https://www.businesswire.com/news/home/20240407836555/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"HrhLzD9Z6tnFxrrcpOYXM4BRrihB6EZF5WQyLPjZQkJ6lmD5bWkRmd","news_summary":"SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"Vg2ZFcNnsbA70jiSbx5jdkhDu5KD6mPJIEAvkNzsa8fvxymfwSb18s","date":"Apr 5, 2024","link":"https://www.businesswire.com/news/home/20240404400399/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"kTV2J9VNqREhZ12Hfllb0QJO6WLQtvb1h7ERoBGH2qtjJ3Zjv0eeGF","news_summary":"SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"AAMKq3i8GESsExDM8cSuxQm6DL7dF3RBx6QJdINYJlF2msEYQU8Tef","date":"Mar 14, 2024","link":"https://www.businesswire.com/news/home/20240314157429/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"k1s4vmADIdxik7w2QWS3y5jEOcbiTdPOmtwpRHqdoDD6gJ5Q0rUpj3","news_summary":"SHL Telemedicine Receives Buy Rating with $11.00 Price Target","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"2wUhPgbfmthPQvXFeQrTsiZYUdvIf3kNkNCbiEWZhXX3e6pUGTf7Tl","date":"Feb 1, 2024","link":"https://www.businesswire.com/news/home/20240131123982/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"xiP3Fxby5y9Qgj5CcmpcWIFuEgu50eLgidNxCK870tCfhBqQqcAQ6D","news_summary":"Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"Fi1Fi5Hb3LD9wlOce3SXKZFv2NbRxbrJqtMjyHsDccI3etUAtRgPK0","date":"Dec 19, 2023","link":"https://www.businesswire.com/news/home/20231219860578/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"yiB4M6sPu6ExuFYUHWIE9t9GdkHepb6pF5tBXnZCw8OgH1oNEVY9MC","news_summary":"SHL Telemedicine and BARMER to Highlight Digital Patient Care at BMC Congress 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"rQmqfG1GVOcCHWeXfWQJ3WyC8rChEm0bt8aziIln69AjgqxvLiWmpf","date":"Nov 27, 2023","link":"https://www.businesswire.com/news/home/20231126806466/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"bmd5xlEuWbzAT7C5QGofnXPr82Yt56No3ccWTpovto7oejLkd6QayJ","news_summary":"SHL Telemedicine Introduces SmartHeart® Direct-to-Consumer Membership Plan in the US","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"38HrRx0j4QKlm3xOTE4mEnLzO5kLvHLhT8SeDjGurfhcoh8QY8IY4b","date":"Nov 6, 2023","link":"https://www.businesswire.com/news/home/20231105080250/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"g58z8hjqG5pbu8aBGKE6gNQVMnf6hgyivHabAkm6r7TBWSosdHzfO8","news_summary":"SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"YCT9LYzi90kYHayYLnI3VxW2GBuP8YPRnyr9B8QSqeSGqK5EePCzsw","date":"Oct 23, 2023","link":"https://www.businesswire.com/news/home/20231022143086/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"ZbvjRgcSHFEsCvaf9zXgeS8XwkUdSxGwCPcjb5qNWo6wsu8HSouRsO","news_summary":"SHL Telemedicine Announces Advancements in its Direct-to-Consumer Strategy in the US","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"lWXIatqa2e6rJwH6sBXwLO7oT7H88YfcJAMI8VZwcf9TrfjjDI1xm9","date":"Sep 26, 2023","link":"https://www.businesswire.com/news/home/20230925392069/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"teZD5LnXjG469RenorB4r53LqUbwLdq9ysywki1iwtoFxFJL1VeF2g","news_summary":"SHL Telemedicine's SmartHeart® Technology Shows Remarkable Effects in Mayo Clinic and Imperial College London Trials","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"BaJd1sjXET1t5poPCOI0Ka3F0iBPIxvHdvH3hzbjY0ru34Ld0OcUD2","date":"Sep 21, 2023","link":"https://www.businesswire.com/news/home/20230921320711/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"W0iZUZ6U1g35O81wZzBLjA0hnf6WIoyvKdeoZhSy62GFlhMhAglAPr","news_summary":"SHL Announces Half-Year Results 2023 – Strategic Moves to Accelerate Growth","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"uuEzoGWg7akexWX9cFKU5UjtBTgiBQwx6DrxvYgMwAc3abBRQFURks","date":"Sep 11, 2023","link":"https://www.businesswire.com/news/home/20230910078442/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Telemedicine, Healthcare","company":"SHL Telemedicine Ltd.","layoffs":"N/A","summary":"SHL Telemedicine Ltd. has announced that initial results from trials conducted by the Mayo Clinic and Imperial College London will be presented at the Vulnerable Plaque and Patient Meeting 2023. The trials relate to the use of SHLs SmartHeart® 12-lead ECG technology for remote monitoring of post-heart attack patients at home. The presentations will discuss the benefits of telemedicine in post-Acute Coronary Syndrome care and the incidence of emergency department visits, rehospitalizations, and Major Adverse Cardiovascular Events for patients using SmartHeart® 12 lead ECG.","partners":"Mayo Clinic, Imperial College London","customers":"Mayo Clinic, Imperial College London","investors":"N/A","confidence":9,"key_topics":["Telemedicine","Healthcare","Clinical Trials","Heart Disease","Remote Monitoring"],"date_of_event":"September 11, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Te29aqBfghlizEnzXow3cHHVz7aL45ZaRs0R6bDqy02iKhC4TqEBDi","news_summary":"SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gb0grqyMV9q7Juj1GXxxdNZizISMRtRPtDJJUAhtdYdyhb6h89NuYI","date":"Sep 6, 2023","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-half-year-results-2023-and-conference-call-scheduled-for-september-21-2023-301919050.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Financial Report","company":"SHL Telemedicine Ltd.","layoffs":"N/A","summary":"SHL Telemedicine Ltd., a leading provider of advanced personal telemedicine solutions, announced that it will release its half-year 2023 results before the market opens on Thursday, September 21, 2023. The company will host a conference call for investors, journalists, and analysts to discuss the results. The call will be hosted by Erez Nachtomy, CEO, and Amir Hai, CFO. SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Half-year Results","Telemedicine","Conference Call","Financial Report","Healthcare Technology"],"date_of_event":"September 21, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"g1lAbb5nDNx3YAR687LJPmSnPel3oYC3Fna6QUqlBFISDIW642nJq7","news_summary":"SHL Telemedicine: Half-year results 2023 and Conference Call Scheduled for September 21, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aLSfT1F8uMy0MkVzvRjwUNaPvuw0X3k0amO27uZdpTwULLwcswdekm","date":"Dec 29, 2022","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-announces-confidential-submission-of-draft-registration-statement-for-proposed-nasdaq-listing-301710956.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"listing","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine has confidentially submitted a draft registration statement with the SEC for the registration of its securities under the Exchange Act, in connection with a proposed NASDAQ listing of American Depositary Shares. The company will continue to be listed on the SIX Swiss Exchange and expects to complete the parallel NASDAQ listing following the SEC review process and NASDAQ approval.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["NASDAQ listing","registration statement","securities","Swiss Stock Exchange","telemedicine"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TmDLc15qSF2Fe5VX24KFnrYSeGVvm0dlKqgLJRbUDweuomLLZ5uevo","news_summary":"SHL Telemedicine announces Confidential Submission of Draft Registration Statement for Proposed NASDAQ Listing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JwRTpL8iL64BU4yrrPs5ohvr4xWdQ6tTNEFeHQEJ4ncNrYDZyfUAk7","date":"Dec 1, 2022","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-to-present-at-ladenburg-thalmann-virtual-technology-expo-on-december-7th-301691331.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"presentation","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine will be presenting virtually at the Ladenburg Thalmann Virtual Technology Expo. The presentation will be given by the CEO and CFO of SHL Telemedicine. SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and medical call center services. The company offers its services and devices to subscribers using telephonic and Internet communication technology. The presentation is scheduled for Wednesday, December 7th, 2022.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["virtual presentation","Ladenburg Thalmann Virtual Technology Expo","personal telemedicine solutions","SHL Telemedicine","forward-looking statements"],"date_of_event":"2022-12-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fzOsDWE0DzRiExBRUjvfBMdMg4zZQQ8OcwLnXtlD0PuZJYkPKlxPKk","news_summary":"SHL Telemedicine to present at Ladenburg Thalmann Virtual Technology Expo on December 7th","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IWECexc0HTIzRNndppWjIdAy1252E82WlnpCffWXzbT46CzODNo91Z","date":"Sep 20, 2022","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-signs-partnership-with-white-rock-medical-center-for-use-of-smartheart-301628034.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"telemedicine, healthcare","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine has entered into an agreement with White Rock Medical Center to use its SmartHeart® technology for pre-surgery physicals in remote locations. This collaboration will improve convenience and access for patients. White Rock Medical Center is known for its comprehensive surgical bariatric program. SHLs SmartHeart® technology is a portable, digital, hospital-grade, 12 Lead ECG solution. The partnership aligns with White Rock Medical Centers vision, and SHL looks forward to expanding the use of SmartHeart® into other specialties.","partners":["White Rock Medical Center"],"customers":null,"investors":null,"confidence":9,"key_topics":["SmartHeart® technology","remote locations","bariatric surgery programs","White Rock Medical Center","collaboration"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dsNSOgppYoxkZqjY7Cl52pv7GqEIKZ8mhq0neNfpu3cL2OOwuZLPKr","news_summary":"SHL Telemedicine signs partnership with White Rock Medical Center for use of SmartHeart®","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2qwQuYq1HEq2u6Na41SN4VH72Fp7F9IUCd3zMSyYMvcFiNcYfb4Sm0","date":"Jul 27, 2022","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-bolsters-its-us-advisory-board-as-the-growth-of-its-smartheart-solution-accelerates-301594094.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"telemedicine, advisory board","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine has appointed Dr. Kimberly J. Henderson and Dr. Joshua H. Atkins to its US Advisory Board as part of its strategy to expand the use of SmartHeart® technology in the US. Dr. Henderson has extensive experience in emergency medicine and medical management, while Dr. Atkins is an academic anesthesiologist with expertise in respiratory monitoring and patient safety. The addition of these key opinion leaders is expected to provide insight and guidance for SHL Telemedicines fast growth in the US market. SHL Telemedicine is a leading provider of personal telemedicine solutions focused on cardiovascular and related diseases.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["SHL Telemedicine","US Advisory Board","SmartHeart® technology","Key Opinion Leaders","Expansion in the US"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zsJrFvkGl73b2VLUiDTYuUJwCXqjPxsw8JrazgHZpIURDbitJkwK7Y","news_summary":"SHL Telemedicine bolsters its US Advisory Board as the growth of its SmartHeart® solution accelerates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5f871196-0751-4203-ba8b-061bcec4e689","date":"Jun 30, 2022","link":"https://www.prnewswire.com/il/news-releases/former-prime-minister-of-israel-ehud-barak-to-be-appointed-as-co-chairman-and-leading-partner-of-shls-global-growth-301578416.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"appointment","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine has announced the appointment of Mr. Ehud Barak as Co-Chairman. Barak will join SHLs senior management team and focus on the companys international growth efforts, particularly in the US and Germany. SHL is a leading provider of telemedicine solutions and has strategic cooperation with major healthcare institutes. The appointment is expected to support the execution and realization of SHLs strategic global vision. The terms of Baraks engagement will be brought for approval by a Special General Meeting of the Shareholders.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Ehud Barak","telemedicine","strategic cooperation","international growth","senior management"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mcdb7e8JwkrYl48EY0lTcuFywVdn2mSoZjcCwzuonbhf3zGdi12cgb","news_summary":"Former Prime Minister of Israel Ehud Barak to be appointed as Co-Chairman and leading partner of SHL's global growth","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZorPKcNw1wuyPe9qk9ygoGKlOkJ6bFgyNq96uhjeSOx5hQG0f4tSCW","date":"Jun 30, 2022","link":"https://finance.yahoo.com/news/former-prime-minister-israel-ehud-120000710.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"9sggFfURn2WAET1VWBzHCS6TyWVFd6jRpgugy7aPcb4CprcWLrIBcK","news_summary":"Former Prime Minister of Israel Ehud Barak to be appointed as Co-Chairman and leading partner of SHL's global growth","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"imlzxktA2iyarmtHvmNpHzsnqwnAovZsVc6JpnBQk4ECM6nNuOfmud","date":"Jun 23, 2022","link":"https://www.prnewswire.com/news-releases/shl-telemedicine-to-appoint-jason-m-bottiglieri-a-highly-experienced-healthcare-executive-as-general-manager-of-shl-telemedicine-usa-301573952.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes, Expand","company":"SHL Telemedicine Ltd.","layoffs":"N/A","summary":"Jason Bottiglieri has been appointed as the General Manager of SHL Telemedicine USA, Inc., a wholly owned subsidiary of SHL Telemedicine Ltd. Bottiglieri has over 25 years of experience in the cardiovascular device field and has held senior leadership roles at several companies including Invatec, Spectranetics, Cordis, Infraredx, and InnovHeart Srl. He most recently served as the Chief Commercial Officer at Elucid Bioimaging. SHL Telemedicine is a leading provider of advanced personal telemedicine solutions and is listed on the SIX Swiss Exchange.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["New General Manager","Telemedicine","Cardiovascular Devices","Expansion","Leadership"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LWBF7keDPMZjO6ollKYQto3mQhk982XX2HLCDgkYQvxVh0yWfGvV3u","news_summary":"SHL Telemedicine to appoint Jason M. Bottiglieri, a highly experienced healthcare executive, as General Manager of SHL Telemedicine USA","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3fae3210-c313-411a-900e-42e627fc2492","date":"Feb 22, 2021","link":"https://www.marketscreener.com/quote/stock/SHL-TELEMEDICINE-LTD-79328/news/SHL-Telemedicine-announces-it-is-exploring-dual-listing-on-another-leading-Stock-Exchange-in-the-US-32496737/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":"dual-listing","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine Ltd. is exploring the possibility of dual-listing for trading on another stock exchange to expand its investors access and support its strategy of expanding the use of SmartHeart™ technology. The company is considering listing on a leading US stock exchange and the Tel Aviv Stock Exchange. The dual-listing initiative aims to make SHLs activities accessible to international investors and expand its existing investors base.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["expansion","SmartHeart™ technology","dual-listing","stock exchange","international investors"],"date_of_event":"2021-02-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"v2Jn2CZR4Ie8sejJf5iTM0XrEJTsDd9yxDUz3sL1NrHuT6iIVLHMcm","news_summary":"SHL Telemedicine announces it is exploring dual listing on another leading Stock Exchange in the US or on the Tel Aviv Stock Exchange  MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b270bcee-69b6-4c39-b768-4015bd5058e4","date":"Dec 15, 2020","link":"https://www.marketscreener.com/quote/stock/SHL-TELEMEDICINE-LTD-79328/news/SHL-Telemedicine-to-acquire-Jumedi-GmbH-a-developer-of-Digital-Health-technologies-32012119/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":"acquisition","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine Ltd. has announced that its German subsidiary will acquire 100% of Jumedi GmbH, a developer of a modular system for digital health applications. The closing of the transaction is expected at the beginning of next year. The acquisition will strengthen SHLs position in the rapidly growing telemedicine market in Germany.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["SHL Telemedicine","Jumedi GmbH","telemedicine","digital health applications","German Digital Healthcare Act"],"date_of_event":"December 15, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DVgjKkv69JOxVVc8QbuLkR0yoopLXaNYm9Uien4VDJxSennLXL6A5j","news_summary":"SHL Telemedicine to acquire Jumedi GmbH a developer of Digital Health technologies  MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"975dbc80-2c06-4289-b0b6-48aee7fbf6dd","date":"May 29, 2018","link":"https://www.marketscreener.com/SHL-TELEMEDICINE-LTD-79328/news/SHL-to-record-additional-income-in-2018-from-contract-in-Germany-26670669/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":"income, telemedicine","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine Ltd. has generated an income of EUR 6.2 million from cost savings delivered under a Chronic Disease Management Services contract in Germany. The income will be recognized as revenue in the companys 2018 financial statements. The CEO of SHL, Yoav Rubinstein, stated that this payment is evidence of SHLs telemedicine model reducing costs for health insurers and improving the quality of life for patients.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["SHL Telemedicine","Chronic Disease Management Services","Germany","telemedicine","cost savings"],"date_of_event":"May 29, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yrn6vDwpsWs0zr96BjW18MkP7oOw8c5nTNgCyxi6EWlhq1I3dvS1jy","news_summary":"SHL to record additional income in 2018 from contract in Germany  MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a4380d14-92b6-4593-8ac2-644fa23f2518","date":"Apr 12, 2018","link":"https://www.marketscreener.com/SHL-TELEMEDICINE-LTD-79328/news/SHL-announces-election-of-Board-Members-at-AGM-26330982/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":"Annual General Meeting","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine Ltd. announced the election of six members to its Board of Directors at the Annual General Meeting of Shareholders. The elected directors will serve until the next annual general meeting. Former board members terms have terminated, and other candidates were not elected. The attending shareholders also approved other items on the AGM agenda.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Board of Directors","Annual General Meeting","Shareholders"],"date_of_event":"April 12, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"j0fmSumHAPRaWF7OFACLL2Vlgkp3xkyb5mV3pNGLErIFETNGxDBB6g","news_summary":"SHL announces election of Board Members at AGM  MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"876b1855-f478-48e3-bc95-e6b4a065ef31","date":"May 11, 2017","link":"https://www.marketscreener.com/SHL-TELEMEDICINE-LTD-79328/news/SHL-Telemedicine-announces-election-of-Board-Members-at-AGM-24375290/","source":"www.marketscreener.com","visible":1,"analysis":{"tags":"management changes","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine Ltd. announced the election of new board members at their Annual General Meeting. Several directors terminated their service, and Mr. Uzi Blumensohns role as chairman of the board of directors was confirmed unanimously. The attending shareholders approved all other items on the AGM agenda.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Board members","Annual General Meeting","Shareholders","Directors","Chairman"],"date_of_event":"2017-05-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fB8azODeiPositsGUYKDkCfTsEQ5mGoGJ4Xr6zIbWnbR6HaAuuiqNE","news_summary":"SHL Telemedicine : announces election of Board Members at AGM  MarketScreener","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"547bca7e-c4a6-4e70-bdea-2330066d407f","date":"Jul 27, 2015","link":"http://www.globes.co.il/en/article-chinese-investment-co-buying-shl-telemedicine-1001055898","source":"www.globes.co.il","visible":1,"analysis":{"tags":"investment, acquisition","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"Shanghai Jiuchuan, a Chinese investment company, is acquiring 100% of SHL Telemedicines shares at a valuation of $130 million. This represents a strategic investment for Shanghai Jiuchuan to penetrate the Chinese market through SHL Telemedicine, a leading company in the telemedicine field. The acquisition is seen as growth-positive for SHL Telemedicine.","partners":null,"customers":null,"investors":"Shanghai Jiuchuan","confidence":9,"key_topics":["SHL Telemedicine","Shanghai Jiuchuan","valuation","investment","Chinese market"],"date_of_event":"July 27, 2015","valuation_amount":"$130 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"t9J5DcfbIryLMdypm9J1XY0IFyyOhk2ZYOvwRfOvokxasxkMLXX33i","news_summary":"Chinese investment co buying SHL Telemedicine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0d81ec92-1d6f-4f94-a1ce-03cdfd3a12d3","date":"Dec 4, 2012","link":"http://www.globes.co.il/en/article-1000803685","source":"www.globes.co.il","visible":1,"analysis":{"tags":"expansion","company":"SHL Telemedicine Ltd.","layoffs":null,"summary":"SHL Telemedicine is the leading company in its field in Germany and aims to widen the gap between itself and competitors. The company won tenders with two German health funds, IKK Sudwest and AOK Bayern, which will provide a significant boost to its business potential. SHL Telemedicine offers remote monitoring and diagnosis services for congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) patients. The companys solutions help health funds save money by allowing patients to monitor their health at home. The German market is a key focus for SHL Telemedicine, and the company plans to expand into other markets in the future, including Japan and other Asian markets. The company expects to reach revenue of $100 million within three to five years.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Germany","health funds","remote monitoring","CHF","COPD"],"date_of_event":"December 4, 2012","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WlKPufcQQmjhyPM5G6FTsG4QKlFVUavpfIS7lQcpoIB0hwgaYPAhiq","news_summary":"Money time for SHL Telemedicine in Germany","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":63,"techcommunityinvolvement":null,"mediagallery":[{"id":"7656dc9e-46b8-48cf-b435-d9d66b1f3e60","timestamp":"2015-01-13 14:11:52.000000","resources_type":2,"resources_title":"","resources_file_name":"sBav6iT62Sw","alt":"","imageurl":"https://img.youtube.com/vi/sBav6iT62Sw/0.jpg","url":"http://youtu.be/sBav6iT62Sw"},{"id":"70f22a4e-4db6-4dc2-bdcc-c8b14b90f50a","timestamp":"2014-06-25 09:10:30.000000","resources_type":2,"resources_title":"","resources_file_name":"PYCQLPpcZRE","alt":"","imageurl":"https://img.youtube.com/vi/PYCQLPpcZRE/0.jpg","url":"http://youtu.be/PYCQLPpcZRE"}],"tags":["mobile-applications","remote-monitoring","home-care","chronic-disease","cardiology","monitoring","telemedicine","heart-failure","pulmonary","digital-healthcare","ecg","insurance-companies","diagnostics","doctors","software-applications","healthcare-providers"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxivkKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo5OcKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4OuV-aALDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgrgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2C","B2B"],"productstage":"Released","products":["TelePulse","CardioBeeper","TeleWeight","smartheart","Cardio'B","TeleBreather","CCM","CardioSenC","TelePres"],"geomarkets":["Europe","United States","Germany","China","India"],"targetmarkets":[],"marketcapital":33602370,"marketcapitaldate":"2025-07-01T13:04:06.000Z","funding":{"investors":3,"lastfunding":"Undisclosed","totalrounds":3,"fundingstage":"Public","totalfunding":"$109M","publicinvestors":3,"lastpublicfunding":0,"totalpublicrounds":3,"totalpublicfunding":109000000},"team":[{"name":"Yoram Alroy","email":"yoram@shl-telemedicine.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOmQioIJDA","bounced":true,"claimed":0,"founder":0,"urlname":"yoram-alroy","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6b6kmQsM","position":"President & Chairman","last_name":"Alroy","claimtoken":"HwZQooYIbFTvmKi3EMVsf43av4BgWmEu50Y16E3r8flAeyx0SrPRdE","first_name":"Yoram","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yoram-alroy-30357130/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-07 12:08:01.000000","initials":"YA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yariv Alroy","email":"yariv@alroy.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLGF-5EIDA","bounced":false,"claimed":0,"founder":1,"urlname":"yariv-alroy","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAntXrhwkM","position":"Co-founder & CEO","last_name":"Alroy","claimtoken":"4g11tNyrFuQ4cm0hWXuxQbT4fQmP2RbvmnOGbo6uPRqeC4mwU3ofBw","first_name":"Yariv","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yariv-alroy-14a08640/","unsubscribed":false,"is_activeuser":0,"additionalemail":"yariva@shl-telemedicine.com","claimedemaildate":"2023-07-07 12:08:43.000000","initials":"YA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Federico Belen","email":"federicob@shl-telemedicine.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IztmLAKDA","bounced":false,"claimed":0,"founder":0,"urlname":"federico-belen","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgjN7P6QsM","position":"Recruitment & HR Partner","last_name":"Belen","claimtoken":"C5mLJb248Li5VF6BbwRG9RLdyIV5f0jxP3gzYE5YfP1p2gDoqKaQob","first_name":"Federico","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/federico-belen-212596122/","unsubscribed":false,"is_activeuser":1,"additionalemail":"b@shl-telemedicine.com","claimedemaildate":"2023-07-07 12:07:58.000000","initials":"FB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2020-03-03T00:00:00.000Z","crunchbaseid":"shl-telemedicine","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-06-25T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"8ZWilLQUc3HZ0Kt7kMOYpdOxcoW7PfUqMqY49Xbmg62eX8QQE7WUJ3","date":"Mar 2023","amount":"Undisclosed","source":"https://www.prnewswire.com/il/news-releases/shl-telemedicine-to-commence-trading-on-nasdaq-under-the-symbol-shlt-301786425.html","ticker":"SHLT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"cC07Zr9E1ymZjbWxOYWcI5LRdndiJbvEDgWneCblOiDDh8LhGjphjE","date":"Aug 2021","amount":"Undisclosed","source":"https://www.shl-telemedicine.com/news/shl-telemedicine-announces-transformative-accretive-acquisition-of-majority-stake-in-mediton-group-a-leading-b2b-healthcare-services-provider-in-israel/","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Mediton Group","acquiredcompany_mna_id":"64wRpiquhxUuQ9711pxj0ZtMmx72jy0HtLUNnTfGMbTvgN95yb8cDq","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/mediton-group","acquiredcompany_mna_logokey":"$GRyraqqVqhokA7tfwtQ2nupHiivlbkptxESsZnMj79xogUU4aUD325.jpg","acquiredcompany_mna_urlname":"/company_page/mediton-group","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$GRyraqqVqhokA7tfwtQ2nupHiivlbkptxESsZnMj79xogUU4aUD325.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"CCPNSumZriKIzl4s7K2crnZsKV51xfXCRJi5szyzxqCguQ2c7Nz7BN","date":"Jan 2021","amount":"Undisclosed","source":"https://www.bloomberg.com/press-releases/2021-01-25/shl-telemedicine-closed-acquisition-of-jumedi-gmbh-a-developer-of-digital-health-technologies-and-strengthens-leadership-of-its","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Jumedi","acquiredcompany_mna_id":"S57Ka9dOZb9HgP5WHHg7REGN7gax1C3nYXFTwTcn26ZY5B67zHuZyz","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/jumedi","acquiredcompany_mna_logokey":"$3UXZtNutVetBZzURtbm8Ey5wYohQPPFPzTzkijxqH3dFKN4DNEYewe.jpg","acquiredcompany_mna_urlname":"/company_page/jumedi","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$3UXZtNutVetBZzURtbm8Ey5wYohQPPFPzTzkijxqH3dFKN4DNEYewe.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"HswEoHFosevDDMRdR32bF9QMlgvrXUN5Qralql1QxrrqrpXxaBBpwJ","date":"Dec 2020","amount":"$39M","source":"https://www.calcalist.co.il/markets/articles/0,7340,L-3882517,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"More Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/more-investment-house-2","logokey":"$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","tagline":"","urlname":"/investor_page/more-investment-house-2","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaqoLZCAw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"bGQY7yfSiZBLxj9QBwnAxQ6kCsOthmBhwcY4oeSKkTL4QPWg1PoNoI","fundingsubtype":"Institutional Investor","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Meitav Dash","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/meitav-dash","logokey":"$npnwhUCPfccPb9mxlqtedOzhXlchuiRJu9rF9E97V4eICVh5hjV7nr","tagline":"","urlname":"/investor_page/meitav-dash","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCJlumPCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eMiMjFZXAiJOyzzSBnXWsvzQihTy2b6q9HnFKLUjTrdEIDvnb80VT3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$npnwhUCPfccPb9mxlqtedOzhXlchuiRJu9rF9E97V4eICVh5hjV7nr","leadcaption":"","followupcaption":""},{"name":"Valuebase ","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/valuebase","logokey":"$qMAAKKabTFcN0lzypp2E0WZOHUuhDiFwlKgkMXfx4qqRTpfDKYyZKg","tagline":"","urlname":"/investor_page/valuebase","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCFpPaUCQw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"uCM1r2i9WbsFSVyGhrf3oU3hCFI9p57mYLZUEHbssRX3N3b3Qei2z5","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$qMAAKKabTFcN0lzypp2E0WZOHUuhDiFwlKgkMXfx4qqRTpfDKYyZKg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":39000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"GAZWTFAjTbmSUzdBoTMMO0CPqqf45ItrAv4H24ZyP1fkd88jFrLslu","date":"Mar 2015","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-shl-telemedicine-buys-german-co-gph-1001021356","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"GPH","acquiredcompany_mna_id":"xEghINkTzCCQk5yX0ArR5dWqxJp20G8YPTl0OEp8DGPuYo4fDCTLVQ","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/gph","acquiredcompany_mna_logokey":"$vdMtvO9zD2AJcnJRnUHutMJqYSSIu36YNsVBWHwF0gjvw4JKR1dlKW.jpg","acquiredcompany_mna_urlname":"/company_page/gph","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$vdMtvO9zD2AJcnJRnUHutMJqYSSIu36YNsVBWHwF0gjvw4JKR1dlKW.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"f04WQiqVG2jX8t8wexn8xGkGAEoLZ8qsKexdHEl80gyFvNcYhylJlc","date":"Dec 2013","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-shl-telemedicine-buys-german-co-gph-1001021356","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Almeda","acquiredcompany_mna_id":"sK5InfIcOzH4clc7sdLfzcRpvKs4Z60C7jhyXznGbCD8YIodYuXDIb","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/almeda","acquiredcompany_mna_logokey":"$bWy8QS7QAEZpOFJIouOH6XnnvW13eXSbrTVwXhC25NO6vdbfDYSLhS.jpg","acquiredcompany_mna_urlname":"/company_page/almeda","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$bWy8QS7QAEZpOFJIouOH6XnnvW13eXSbrTVwXhC25NO6vdbfDYSLhS.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODI39ifCQw","date":"Apr 2000","amount":"Undisclosed","source":"https://www.themarker.com/misc/2000-11-15/ty-article/0000017f-f311-d8a1-a5ff-f39b05410000 https://he.wikipedia.org/wiki/%D7%A9%D7%97%D7%9C_%D7%98%D7%9C%D7%A8%D7%A4%D7%95%D7%90%D7%94","ticker":"SHLTN.SW","eventtype":"POEvent","valuation":"$220M","investment":[],"capitalraised":"$70M","stockexchange":"SIX","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIkJbHCQw","stockexchange_logokey":"$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":70000000,"valuationnumber":220000000}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/1987","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"SHL Telemedicine","logourl":"https://storage.googleapis.com/clean-finder-353810/$S9E14tNcj9ZrdNPXmbrcSJ7sLTB21dcNeaeBRXxwGJJeDoXMxYYnAG","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$S9E14tNcj9ZrdNPXmbrcSJ7sLTB21dcNeaeBRXxwGJJeDoXMxYYnAG","seoabout":"SHL Telemedicine develops ECG and supporting devices, platforms, and software for home care. The company aims to increase users' chance of survival in the ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Patient Remote Monitoring","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4OuV-aALDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Monitors","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo5OcKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":2,"name":"Mobile","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgrgKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Insurance Companies","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxivkKDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Insurance Companies#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxivkKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Monitors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo5OcKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Patient Remote Monitoring#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4OuV-aALDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Mobile#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgrgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Patient Remote Monitoring#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4OuV-aALDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Monitors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo5OcKDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Diagnostics Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|1:>TechnologyClassificationModel/Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Mobile#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgrgKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Insurance Companies#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxivkKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Patient Remote Monitoring","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Patient Remote Monitoring"}]},{"title":"Medical Devices","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Monitors","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Monitors"},{"title":"Diagnostics Devices","key":"0-0-1-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Diagnostics Devices"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"},{"title":"Patients","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Insurance Companies","key":"0-0-0-2","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Insurance Companies"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence"},{"title":"Platforms & Interfaces","key":"0-1","path":"TechnologyClassificationModel>Platforms & Interfaces","children":[{"title":"Software","key":"0-1-0","path":"TechnologyClassificationModel>Platforms & Interfaces>Software"},{"title":"Mobile","key":"0-1-1","path":"TechnologyClassificationModel>Platforms & Interfaces>Mobile"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Patient Remote Monitoring","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4OuV-aALDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Monitors","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo5OcKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Diagnostics Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lv-484LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":2,"name":"Mobile","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgrgKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Insurance Companies","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxivkKDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Patient Remote Monitoring","Medical Devices","Medical Monitors","Diagnostics Devices"],"coreTechnology":["Artificial Intelligence","Platforms & Interfaces","Software","Mobile"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Providers","Patients","Insurance Companies"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"8ZWilLQUc3HZ0Kt7kMOYpdOxcoW7PfUqMqY49Xbmg62eX8QQE7WUJ3","date":"Mar 2023","amount":"Undisclosed","source":"https://www.prnewswire.com/il/news-releases/shl-telemedicine-to-commence-trading-on-nasdaq-under-the-symbol-shlt-301786425.html","ticker":"SHLT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODI39ifCQw","date":"Apr 2000","amount":"Undisclosed","source":"https://www.themarker.com/misc/2000-11-15/ty-article/0000017f-f311-d8a1-a5ff-f39b05410000 https://he.wikipedia.org/wiki/%D7%A9%D7%97%D7%9C_%D7%98%D7%9C%D7%A8%D7%A4%D7%95%D7%90%D7%94","ticker":"SHLTN.SW","eventtype":"POEvent","valuation":"$220M","investment":[],"capitalraised":"$70M","stockexchange":"SIX","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIkJbHCQw","stockexchange_logokey":"$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":70000000,"valuationnumber":220000000}],"privateequityfunding":[{"id":"HswEoHFosevDDMRdR32bF9QMlgvrXUN5Qralql1QxrrqrpXxaBBpwJ","date":"Dec 2020","amount":"$39M","source":"https://www.calcalist.co.il/markets/articles/0,7340,L-3882517,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"More Investment House","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/more-investment-house-2","logokey":"$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","tagline":"","urlname":"/investor_page/more-investment-house-2","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaqoLZCAw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"bGQY7yfSiZBLxj9QBwnAxQ6kCsOthmBhwcY4oeSKkTL4QPWg1PoNoI","fundingsubtype":"Institutional Investor","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6tGZXu84loSYEHBumfBqR3DvLN7Dz5KmF4rbAYxVxKbKHRhYxDiSme","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Meitav Dash","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/meitav-dash","logokey":"$npnwhUCPfccPb9mxlqtedOzhXlchuiRJu9rF9E97V4eICVh5hjV7nr","tagline":"","urlname":"/investor_page/meitav-dash","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCJlumPCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eMiMjFZXAiJOyzzSBnXWsvzQihTy2b6q9HnFKLUjTrdEIDvnb80VT3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$npnwhUCPfccPb9mxlqtedOzhXlchuiRJu9rF9E97V4eICVh5hjV7nr","leadcaption":"","followupcaption":""},{"name":"Valuebase ","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/valuebase","logokey":"$qMAAKKabTFcN0lzypp2E0WZOHUuhDiFwlKgkMXfx4qqRTpfDKYyZKg","tagline":"","urlname":"/investor_page/valuebase","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCFpPaUCQw","fundingtype":"Institutional Investor","leadpartner":null,"investmentid":"uCM1r2i9WbsFSVyGhrf3oU3hCFI9p57mYLZUEHbssRX3N3b3Qei2z5","fundingsubtype":"Institutional Investor","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$qMAAKKabTFcN0lzypp2E0WZOHUuhDiFwlKgkMXfx4qqRTpfDKYyZKg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":39000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[{"id":"cC07Zr9E1ymZjbWxOYWcI5LRdndiJbvEDgWneCblOiDDh8LhGjphjE","date":"Aug 2021","amount":"Undisclosed","source":"https://www.shl-telemedicine.com/news/shl-telemedicine-announces-transformative-accretive-acquisition-of-majority-stake-in-mediton-group-a-leading-b2b-healthcare-services-provider-in-israel/","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Mediton Group","acquiredcompany_mna_id":"64wRpiquhxUuQ9711pxj0ZtMmx72jy0HtLUNnTfGMbTvgN95yb8cDq","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/mediton-group","acquiredcompany_mna_logokey":"$GRyraqqVqhokA7tfwtQ2nupHiivlbkptxESsZnMj79xogUU4aUD325.jpg","acquiredcompany_mna_urlname":"/company_page/mediton-group","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$GRyraqqVqhokA7tfwtQ2nupHiivlbkptxESsZnMj79xogUU4aUD325.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"CCPNSumZriKIzl4s7K2crnZsKV51xfXCRJi5szyzxqCguQ2c7Nz7BN","date":"Jan 2021","amount":"Undisclosed","source":"https://www.bloomberg.com/press-releases/2021-01-25/shl-telemedicine-closed-acquisition-of-jumedi-gmbh-a-developer-of-digital-health-technologies-and-strengthens-leadership-of-its","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Jumedi","acquiredcompany_mna_id":"S57Ka9dOZb9HgP5WHHg7REGN7gax1C3nYXFTwTcn26ZY5B67zHuZyz","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/jumedi","acquiredcompany_mna_logokey":"$3UXZtNutVetBZzURtbm8Ey5wYohQPPFPzTzkijxqH3dFKN4DNEYewe.jpg","acquiredcompany_mna_urlname":"/company_page/jumedi","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$3UXZtNutVetBZzURtbm8Ey5wYohQPPFPzTzkijxqH3dFKN4DNEYewe.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"GAZWTFAjTbmSUzdBoTMMO0CPqqf45ItrAv4H24ZyP1fkd88jFrLslu","date":"Mar 2015","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-shl-telemedicine-buys-german-co-gph-1001021356","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"GPH","acquiredcompany_mna_id":"xEghINkTzCCQk5yX0ArR5dWqxJp20G8YPTl0OEp8DGPuYo4fDCTLVQ","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/gph","acquiredcompany_mna_logokey":"$vdMtvO9zD2AJcnJRnUHutMJqYSSIu36YNsVBWHwF0gjvw4JKR1dlKW.jpg","acquiredcompany_mna_urlname":"/company_page/gph","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$vdMtvO9zD2AJcnJRnUHutMJqYSSIu36YNsVBWHwF0gjvw4JKR1dlKW.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"f04WQiqVG2jX8t8wexn8xGkGAEoLZ8qsKexdHEl80gyFvNcYhylJlc","date":"Dec 2013","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-shl-telemedicine-buys-german-co-gph-1001021356","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Almeda","acquiredcompany_mna_id":"sK5InfIcOzH4clc7sdLfzcRpvKs4Z60C7jhyXznGbCD8YIodYuXDIb","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/almeda","acquiredcompany_mna_logokey":"$bWy8QS7QAEZpOFJIouOH6XnnvW13eXSbrTVwXhC25NO6vdbfDYSLhS.jpg","acquiredcompany_mna_urlname":"/company_page/almeda","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$bWy8QS7QAEZpOFJIouOH6XnnvW13eXSbrTVwXhC25NO6vdbfDYSLhS.jpg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}